GILD241122P55000
- 0.00
- 0.000.00%
Gilead Sciences Newsroom
S&P Sees Some Signs of a US Credit Bubble as Spreads Tighten
Monday Market Slow but Steady, Trump Buying Crypto Firm | Wall Street Today
Monday Opens to S&P 500 Climb, Dow Slides as Eyes Look Toward Nvidia | Live Stock
26 Analysts Assess Gilead Sciences: What You Need To Know
Daiwa Securities Adjusts Gilead Sciences Price Target to $90 From $73
Gilead Sciences Is Maintained at Sector Perform by RBC Capital
Gilead Sciences Analyst Ratings
Express News | Gilead : RBC Raises Target Price to $84 From $81
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
US Manufacturing Index Rises To 43, Highest Since 2020
Weekly Buzz: Not All Parties Last Forever
Market Falls to End All-Time High Week | Wall Street Today
Express News | Shares of Pharmaceutical and Healthcare Stocks Are Trading Lower. The Sector Has Been Under Pressure After President-elect Trump Nominated Robert F. Kennedy Jr. to Lead the HHS
Sell-off of US vaccine stocks intensifies! Analyst: Little Kennedy brings uncertainty to the entire industry.
1. On Friday Eastern Time, vaccine manufacturers' stocks plummeted as Donald Trump selected vaccine skeptic Kennedy as Health Secretary, causing industry uncertainty. Moderna, Novavax, Pfizer, and other stock prices were all affected. 2. Analysts pointed out that Kennedy's anti-vaccine stance may weaken public trust in vaccines, leading to a decrease in the vaccination rate in the USA, increasing the risk of outbreaks of diseases such as measles and whooping cough.
Large Pharmas, Biotechs Down as Industries Grapple With RFK Jr. at HHS
U.S. Pharma Is Largely Immune From 'MAHA' Impact: Wolfe
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Gilead on Pace for Largest Percent Decrease Since February -- Data Talk
Gilead Sciences Says Most of Phase 3 Primary Biliary Cholangitis Participants Treated With Livdelzi Achieved Biochemical Response
Market Falls Friday After Light Earnings and 13F's | Live Stock